2 Minute Medicine

No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Lenalidomide shows improvement in progression-free survival over bortezomib maintenance following autologous stem cell transplantation for multiple myeloma

byKathleen Lau

January 28, 2021

in StudyGraphics

RELATED REPORTS

FDA grants priority review for iberdomide-based myeloma regimen

Replacing sedentary time with physical activity may lower risk of all-cause mortality

2 Minute Medicine: Pharma Roundup – Merck and Mayo Clinic’s AI precision medicine lab, Novartis’ remibrutinib hits Phase III hive endpoint, FDA grants priority review for iberdomide in myeloma, oral infigratinib boosts growth velocity in achondroplasia, and shingles vaccine/sildenafil linked to lower Alzheimer’s risk [February 2026]

Tags: asct astct autologous stem cell transplant autologous stem cell transplantation blood blood cancer bortezomib cancer complete response hematology induction infection lenalidomide leukopenia maintenance maintenance therapy multiple myeloma myeloma near complete response neutropenia newly diagnosed newly diagnosed multiple myeloma no significant difference oncology overall survival pfs post-asct progression-free survival standard of care stem cell stem cell transplant survival survival outcomes tandem asct

#VisualAbstract: Prognosis for advanced melanoma has improved between 2013 to 2017 for patients in the Netherlands

Machine learning-based PRAISE score may aid in the prediction of adverse events following an acute coronary syndrome

RelatedReports

Variation noted across pre- and post-marketing studies for FDA approved devices

Hematology

FDA grants priority review for iberdomide-based myeloma regimen

Reduced gestational weight gain with lifestyle intervention

Cardiology

Replacing sedentary time with physical activity may lower risk of all-cause mortality

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]

Chronic Disease

2 Minute Medicine: Pharma Roundup – Merck and Mayo Clinic’s AI precision medicine lab, Novartis’ remibrutinib hits Phase III hive endpoint, FDA grants priority review for iberdomide in myeloma, oral infigratinib boosts growth velocity in achondroplasia, and shingles vaccine/sildenafil linked to lower Alzheimer’s risk [February 2026]

February 26, 2026

2MM: AI Roundup- AI Cancer Test, Smarter Hospitals, Faster Drug Discovery, and Mental Health Tech [May 2nd, 2025]

AI Roundup

Artificial intelligence predicts colorectal cancer in ulcerative colitis with 99% accuracy

February 20, 2026

Next Post

Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis

Machine learning-based PRAISE score may aid in the prediction of adverse events following an acute coronary syndrome

Tamsulosin therapy associated with significant reduction of symptoms of overactive bladder

Laryngeal mask airway may not be superior for neonate resuscitation

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

No Result

View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.